Stealth BioTherapeutics Completes Mid-Cycle Review Meeting on Elamipretide for the Treatment of Barth Syndrome

Company is preparing for Advisory Committee Meeting with the Cardiovascular and Renal Drugs Advisory Committee NEEDHAM, Mass., July 29, 2024 /PRNewswire/ — Stealth BioTherapeutics Inc. (the “Company” or “Stealth”), a clinical-stage biotechnology company focused on the discovery,…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.